Ampio Pharmaceuticals Appoints Mark McGregor as CFO
Ampio Pharmaceuticals has appointed Mark McGregor as chief financial officer (CFO) and corporate secretary. Bruce Miller, who served in these capacities since April 2010, will be joining the team that will advance the commercialisation of Zertane, Ampio’s product candidate that was the subject of a 2009 and 2010 Phase 3 multicenter clinical trial in Europe and was obtained through the acquisition of DMI BioSciences. Miller was with DMI BioSciences since 1992, having served as chief executive officer (CEO) and/or president throughout this period.
McGregor, a certified public accountant (CPA), is an experienced financial executive with in-depth experience in treasury and risk management, including developing financial strategic plans, cash management and investments, managing foreign currency and interest rate exposures, credit provider and credit rating agency relations, and insurance risk management.
McGregor’s career spans over 30 years of financial experience in a variety of industries. For 20 years he was with Storage Technology, a public international information and storage technology company with US$2bn in annual worldwide revenues, where he served in a variety of financial positions and advanced to vice president, corporate treasurers and corporate development. McGregor was directly involved in two divestitures and four acquisitions while with Storage Technology, in addition to leading the deal team in connection with the sale of StorageTek to Sun Microsystems in 2005. He began his career with Price Waterhouse, now PricewaterhouseCoopers (PwC), where he spent 13 years with the audit department.